{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:40:03Z","timestamp":1792003203520,"version":"4.4.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec id=\"ab-soi220060-4\"><jats:title>Importance<\/jats:title><jats:p>Several less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients with initially clinically node-positive (cN+) breast cancer, but these procedures may fail to detect residual disease. Owing to the lack of high-level evidence, it is not yet clear which procedure is most optimal to replace ALND.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS), a targeted axillary dissection procedure.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a prospective, multicenter, noninferiority, diagnostic accuracy trial conducted from March 1, 2017, to December 31, 2019. Patients were included within 14 institutions (general, teaching, and academic) throughout the Netherlands. Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter &amp;amp;lt;2 cm and up to &amp;amp;gt;5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and\/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and\/or level II axillary nodes; cN3b, metastases to ipsilateral level I and\/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion. Data were analyzed from July 2020 to December 2021.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-7\"><jats:title>Intervention<\/jats:title><jats:p>Pre-NAC, the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the marked lymph node (ie, RISAS procedure) was performed, followed by ALND.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The identification rate, false-negative rate (FNR), and negative predictive value (NPV) were calculated for all 3 procedures: RISAS, SLNB, and MARI. The noninferiority margin of the observed FNR was 6.25% for the RISAS procedure.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-9\"><jats:title>Results<\/jats:title><jats:p>A total of 212 patients (median [range] age, 52 [22-77] years) who had cN+ breast cancer underwent the RISAS procedure and ALND. The identification rate of the RISAS procedure was 98.2% (223 of 227). The identification rates of SLNB and MARI were 86.4% (197 of 228) and 94.1% (224 of 238), respectively. FNR of the RISAS procedure was 3.5% (5 of 144; 90% CI, 1.38-7.16), and NPV was 92.8% (64 of 69; 90% CI, 85.37-97.10), compared with an FNR of 17.9% (22 of 123; 90% CI, 12.4%-24.5%) and NPV of 72.8% (59 of 81; 90% CI, 63.5%-80.8%) for SLNB and an FNR of 7.0% (10 of 143; 90% CI, 3.8%-11.6%) and NPV of 86.3% (63 of 73; 90% CI, 77.9%-92.4%) for the MARI procedure. In a subgroup of 174 patients in whom SLNB and the MARI procedure were successful and ALND was performed, FNR of the RISAS procedure was 2.5% (3 of 118; 90% CI, 0.7%-6.4%), compared with 18.6% (22 of 118; 90% CI, 13.0%-25.5%) for SLNB (<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and 6.8% (8 of 118; 90% CI, 3.4%-11.9%) for the MARI procedure (<jats:italic>P<\/jats:italic>\u2009=\u2009.03).<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi220060-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results of this diagnostic study suggest that the RISAS procedure was the most feasible and accurate less-invasive procedure for axillary staging after NAC in patients with cN+ breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2022.3907","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T15:04:22Z","timestamp":1662563062000},"page":"991","source":"Crossref","is-referenced-by-count":104,"title":["Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer"],"prefix":"10.1001","volume":"157","author":[{"given":"Janine M.","family":"Simons","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"},{"name":"Department of Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"},{"name":"Department of Surgical Oncology, Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo J. A.","family":"van Nijnatten","sequence":"additional","affiliation":[{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C.","family":"van der Pol","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Department of Surgical Oncology, Alrijne Hospital, Leiderdorp, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Klaveren","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L. R.","family":"Kam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands"},{"name":"Department of Nuclear Medicine, Diakonessenhuis, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc B. I.","family":"Lobbes","sequence":"additional","affiliation":[{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, the Netherlands"},{"name":"Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"de Boer","sequence":"additional","affiliation":[{"name":"GROW-School for Oncology and Reproduction, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R. A.","family":"Sars","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Bravis Hospital, Roosendaal, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald J.","family":"Heijmans","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hospital Group Twente, Breast Clinic Oost-Nederland, Hengelo, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els R. M.","family":"van Haaren","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Zuyderland Medical Center, Sittard, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Vles","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ikazia Hospital, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M. E.","family":"Contant","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Maasstad Hospital, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian B. E.","family":"Menke-Pluijmers","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Albert Schweitzer Hospital, Dordrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onie H. M.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Treant Zorggroep Hospital, Hoogeveen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Kelder","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Martini Hospital, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike","family":"Boskamp","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Wilhelmina Hospital, Assen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta B.","family":"Koppert","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest J. T.","family":"Luiten","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Amphia Hospital, Breda, the Netherlands"},{"name":"Tawam Breast Care Center, Tawam Hospital, Al Ain, Abu Dhabi Emirate, United Arab Emirates"},{"name":"Department of Surgery College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, Abu Dhabi Emirate, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands"},{"name":"Deparment of Surgical Oncology, Maastricht University Medical Center+, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"soi220060r1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis.","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"},{"issue":"12","key":"soi220060r2","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.v116:12","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"soi220060r3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy.","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"soi220060r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis.","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"soi220060r5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"soi220060r6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"soi220060r7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"soi220060r8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"8","key":"soi220060r9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/bjs.7073","article-title":"Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer.","volume":"97","author":"Straver","year":"2010","journal-title":"Br J Surg"},{"issue":"10","key":"soi220060r10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"soi220060r11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance).","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"issue":"3","key":"soi220060r12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated With Neoadjuvant Therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment.","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"Nov","key":"soi220060r13","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004572","article-title":"A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients.","author":"Kuemmel","year":"2020","journal-title":"Ann Surg"},{"issue":"5","key":"soi220060r14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","article-title":"A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): a Dutch prospective multicenter validation study.","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"soi220060r16","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","article-title":"Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy.","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"soi220060r17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"soi220060r18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"soi220060r23","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.clbc.2021.07.011","article-title":"MINImal vs MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: protocol of a Dutch multicenter registry study (MINIMAX).","volume":"22","author":"de Wild","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"soi220060r24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","article-title":"De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.","volume":"180","author":"Simons","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"soi220060r25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-017-6263-y","article-title":"Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype.","volume":"25","author":"Al-Hilli","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"soi220060r26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jamcollsurg.2016.12.036","article-title":"Axillary management of stage II\/III breast cancer in patients treated with neoadjuvant systemic therapy: results of CALGB 40601 (HER2-positive) and CALGB 40603 (triple-negative).","volume":"224","author":"Ollila","year":"2017","journal-title":"J Am Coll Surg"},{"issue":"9","key":"soi220060r27","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","article-title":"Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy.","volume":"25","author":"Nguyen","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"soi220060r15","unstructured":"RISAS procedure in node-positive breast cancer following NAC (RISAS). ClinicalTrials.gov identifier: NCT02800317. Updated February 10, 2022. Accessed Month Day, Year. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02800317"},{"key":"soi220060r19","unstructured":"Axillary management in breast cancer patients with needle biopsy proven nodal metastases after neoadjuvant chemotherapy (ATNEC). ClinicalTrials.gov identifier: NCT04109079. Updated June 1, 2022. Accessed July 3, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04109079"},{"key":"soi220060r20","unstructured":"Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. ClinicalTrials.gov identifier: NCT01872975. Updated May 9, 2022. Accessed July 3, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01872975"},{"key":"soi220060r21","unstructured":"Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. ClinicalTrials.gov identifier: NCT01901094. Updated August 3, 2022. Accessed July 3, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094"},{"key":"soi220060r22","unstructured":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in clinically node-positive breast cancer (TAXIS). ClinicalTrials.gov identifier: NCT 03513614. Updated November 23, 2021. Accessed July 3, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03513614"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2795851\/jamasurgery_simons_2022_oi_220060_1667884256.66125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:06:01Z","timestamp":1668009961000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2795851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2022.3907","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}